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Abstract
High-density lipoprotein cholesterol (HDL-c) has long been referred to as ‘good cholesterol’ due to its apparent inverse relationship
with future CVD risk.More recent research has questioned a causal role for HDL-c in this relationship, however, as both genetic studies
and numerous large-scale randomised controlled trials have found no evidence of a cardiovascular protective effect whenHDL-c levels
are raised. Instead, focus has switched to the functional properties of theHDL particle. Evidence suggests that both the composition and
function of HDLmay be significantly altered in the context of an inflammatory milieu, transforming the particle from a vasoprotective
anti-atherogenic particle to a noxious pro-atherogenic equivalent. This review will summarise evidence relating HDL to CVD risk,
explore recent evidence characterising changes in the composition and function of HDL that may occur in chronic inflammatory
diseases, and discuss the potential for future HDL-modifying therapeutic interventions.
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Introduction
High-density lipoproteins (HDL) participate in the transfer of
excess cholesterol from peripheral sites to the liver, and the
cholesterol carried within these lipoproteins (HDL-c) is there-
fore often referred to as ‘good cholesterol’. Over the past half-
century, HDL-c has repeatedly been shown to be inversely
associated with risk of future cardiovascular events, and has
therefore become one of the most well-known and widely
studied risk factors for cardiovascular disease (CVD). Recent
research, however, has called the causal nature of this relation-
ship into question, with genetic studies finding little evidence
of an association between elevated HDL-c levels and reduced
CVD risk [1, 2], and a series of major clinical trials failing to
demonstrate any clinical benefit when HDL-c levels were
pharmacologically raised [3–7]. Recent insights into the com-
plex structural and functional properties of HDL particles—
and their vulnerability tomodification when exposed to a range
of CV risk factors, particularly inflammation—have shed light
on the potential reasons for these negative findings, and have
posed the question as to whether focusing on the ‘quality’
rather than quantity of HDL may be a more relevant target
for drug development. This review will summarise previous
research attempting to reduce CVD risk through the modifica-
tion of HDL-c levels, explore recent evidence characterising
changes in the composition and function of HDL that may
occur in chronic inflammatory diseases, and discuss the poten-
tial for future HDL-modifying therapeutic interventions.
HDL-C and Cardiovascular Risk: When
Correlation Does Not Equal Causation
The concept of HDL-c as a beneficial lipid was first proposed
in the Framingham Heart Study in the latter half of the twen-
tieth century, where low levels of HDL-c were found to be an
independent risk factor for future incidence of coronary heart
disease (CHD) in 2815 men and women over 12 years of
follow-up [8, 9]. The replication of these findings in further
large-scale cohorts suggested a protective role for HDL-c in
the atherosclerotic process [10, 11], leading to the adoption of
HDL-c’s well-known description as a form of “good choles-
terol”. Despite robust relationships in epidemiological studies,
however, the observational nature of these findings long
meant that the question of whether HDL-c played a direct role
in the disease process—or was simply a biomarker of other
underlying complications—remained uncertain.
Disappointingly, a number of findings from genetic studies
and numerous large-scale randomised clinical trials in the last
10–15 years have suggested the latter. Firstly, the develop-
ment of genome-wide association studies (GWAS) and
Mendelian Randomization studies in the early 2000s allowed
the causal nature of this relationship to be investigated for the
first time using HDL-raising genetic variants in large obser-
vational studies as proxy measures for cumulative HDL-c ex-
posure . F indings f rom two separa te Mende l ian
Randomization studies containing over 165,000 participants
found no association between genetically determined HDL-c
and risk of myocardial infarction, despite traditional observa-
tional relationships from the same cohorts displaying the ex-
pected inverse relationship with plasma levels of HDL-c [1,
2]. These findings challenged the concept that elevating HDL-
c would translate into clinical benefit, and these concerns were
later confirmed by negative findings from numerous
randomised clinical trials investigating a number of different
HDL-raising drugs. Perhaps the most well-known of these
failures was that of the ILLUMINATE trial, a randomised
clinical trial investigating the use of torcetrapib in > 15,000
individuals at high risk of CVD, and the first major trial in-
volving a recently developed class of drugs known as choles-
terol ester transfer protein (CETP)-inhibitors. As the name
suggests, this drug class—which included the agents
torcetrapib, dalcetrapib, evacetrapib, anacetrapib, and
obicetrapib—was designed to block CETP; the enzyme re-
sponsible for transferring cholesterol esters away from HDL
and on to VLDL/LDL. Despite raising HDL-c levels by over
70%, ILLUMINATEwas forced to terminate prematurely due
to an increased risk of CV events and mortality in patients
taking the drug, most likely due to off-target effects on
aldosterone production and blood pressure [3]. The devel-
opment of different forms of this drug that lacked these off-
target effects maintained hope for CETP-inhibitors as a
therapeutic target, but results from later trials proved once
again disappointing, with both the dal-OUTCOMES
(dalcetrapib) and ACCELERATE (evacetrapib) trials show-
ing no benefit of treatment despite significant increases in
HDL-c [4, 5]. Although a rare positive outcome was re-
ported for anacetrapib—the final CETP-inhibitor to be test-
ed in the recent HPS3/TIMI55-REVEAL trial—this was
concluded to have likely resulted from a further lowering
of LDL-c rather than the observed elevation in HDL-c [12].
Alongside CETP-inhibitors, the early 2000s also saw the
design and completion of a number of trials investigating
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extended release niacin, an agent shown to consistently
elevate HDL-c via numerous distinct pathways—including
(but not limited to) an upregulation of ApoA-I production,
a reduction in CETP activity, and a reduction in hepatic uptake of
HDL [13]. In the first of these studies (AIM-HIGH), the addition
of niacin to statin treatment in >3400 patients showed no evi-
dence of clinical benefit, leading the trial to be terminated early
due to lack of efficacy [6], whereas in the later HPS2-THRIVE
trial, extended release niacin not only had no clinical benefit, but
was in fact found to increase risk of serious adverse events [7].
Taken together, findings from these trials appear to have ended
the concept that elevated levels of HDL-c act as a protective
factor against atherosclerotic disease, and efforts to reduce
CVD risk through pharmacological manipulation of HDL-c are
therefore no longer being pursued.
HDL Function and Cardiovascular Risk: a Shift
of Focus from ‘Quantity’ to ‘Quality’
Given the wide range of anti-atherogenic properties attributed to
the HDL particle in decades of animal research and preclinical
studies, the discovery that HDL-c lacked a causal role in CVD
risk was initially unexpected. However, the majority of function-
al properties exerted by HDL are not dependent on the choles-
terol content of the particle per se, but rather on numerous other
structural components contained within the complex and highly
heterogenous HDL particle. Therefore, with the end of the HDL-
c hypothesis in the early 2000s came the start of the HDL func-
tion hypothesis—characterised by a focus on the functional ca-
pacity of HDL particles, rather than their absolute cholesterol
levels alone.
In the basal state, HDL’s functional properties are predomi-
nantly anti-atherogenic; the most well-studied of which is its
ability to facilitate the removal of excess cholesterol from athero-
sclerotic plaques in a process known as reverse cholesterol trans-
port (RCT). In addition to RCT, however, HDL has also been
shown to have multiple other vascular effects which may be
expected to provide additional protection; such as an ability to
increase endothelial nitric oxide (NO) bioavailability, a capacity
to reduce oxidative stress and inflammation, and an ability to
reduce the expression of endothelial adhesion markers and
transendothelial monocyte migration [14].More recent evidence,
however, has highlighted the presence of numerous structural
and functional changes in the HDL particle that may result in
its transformation from an anti-atherogenic vasoprotective parti-
cle to a pro-inflammatory noxious equivalent (Fig. 1). These
alterations are most commonly observed in the presence of sys-
temic inflammation, and suggest an evolutionary role for HDL in
the innate immune response, where the greatest threat to human
longevity has long come from viral or bacterial infections [15].
With long-term chronic inflammatory conditions such as CHD
or type 2 diabetes (T2D) now prevalent in the population, how-
ever, the possibility exists that this previously ‘protective’ re-
sponse may now paradoxically accelerate vascular damage and
increase the risk of mortality via atherosclerotic complications.
Fig. 1 Potential mechanisms
linking dysfunctional HDL to
vascular damage. In the absence
of inflammation (top), HDL
exerts vascular protective effects
through its ability to increase
endothelial NO bioavailability,
decrease oxidative stress, and
inhibit the expression of adhesion
molecules on the vascular wall. In
inflammatory states (bottom),
however, numerous structural and
functional changes may occur and
compromise endothelial function.
Beneficial proteins contained
within the particle (e.g. ApoA-I,
PON-1) are liable for oxidation or
replacement, resulting in a
noxious particle which impairs
NO generation, amplifies
oxidative stress, and promotes
adhesion molecule expression
and monocyte infiltration across
the vascular wall
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The remainder of this review will therefore seek to address
this topic, beginning with (1) evidence surrounding the anti-
atherogenic role for HDL, (2) changes in its structure and
function that may accompany chronic inflammation, (3) the
implications these changes have for CVD risk in different
clinical populations and (4) what this may mean for HDL as
a risk marker or therapeutic target.
HDL Structure and Function in Healthy
Individuals: an Anti-atherogenic Particle
Exerting Multiple Vasoprotective Effects
HDL Structure
The term HDL in fact refers to a highly heterogeneous range
of particles within human plasma, ranging in size from 5 to
17 nm and density from 1.063–1.210 kg/l. Alongside choles-
terol, lipidomic and proteomic techniques have identified over
200 additional lipids and more than 85 proteins which may
reside within the HDL particle [16, 17], as well as multiple
enzymes and even genetic material in the form ofmicro RNAs
(Table 1). Significant variation in the relative quantities of
these components results in a wide spectrum of circulating
HDL particles that may differ in size, density, structure, and
function. For ease of assessment, however, these are common-
ly separated into five broad subclasses, ranging from the larg-
est and least dense (termed HDL2b) to the smallest and most
dense (termed HDL3b). The major structural protein compo-
nent of HDL is apolipoprotein A-I (apoA-I), formed in both
the liver (~ 80%) and intestine (~ 20%) and secreted in a lipid-
free state. Efflux of phospholipids and free cholesterol on to at
least 2 molecules of apoA-I stimulate the biogenesis of HDL,
resulting in the generation of a discoidal lipid-poor ‘nascent’
HDL particle. Subsequent incorporation of numerous en-
zymes such as lecithin-cholesterol acyltransferase (LCAT),
cholesterol ester transfer protein (CETP) and phospholipid
transfer protein (PLTP) into this nascent particle further alter
the lipid and phospholipid composition—resulting in the gen-
eration of mature spherical particles of differing sizes and
densities. These particles may be further modified through
the incorporation of numerous other structural proteins and
enzymes (shown in Table 1) all of which interact to determine
the eventual functional capabilities of the HDL particle [18].
Reverse Cholesterol Transport
The concept of HDL as a shuttle for removing excess choles-
terol from lipid-laden macrophages within peripheral tissues
was first proposed over 50 years ago [19], and since then has
become one of the most well-recognised pathways underlying
HDL’s anti-atherogenic nature (Fig. 2). When cell cholesterol
content is normal, this process is dominated via the passive
aqueous diffusion of free cholesterol between cell membranes
and HDL [20]. Although this pathway is bidirectional, ester-
ification of free cholesterol within HDL by the enzyme LCAT
maintains a concentration gradient promoting efflux out of the
cells, thereby preventing its accumulation in cell membranes
and maintaining homeostasis. In addition to passive diffusion,
non-aqueous efflux may also occur through the binding of
HDL to scavenger receptor class B1 (SR-BI), with this path-
way shown to be enhancedwhen absolute HDL levels are low,
or HDL particle size is large [21]. When cell cholesterol con-
tent is elevated, however—as is the case in atherogenic lipid-
laden macrophages—a shift to active efflux pathways medi-
ated through the upregulation of the ATP-binding cassette
transporters ABCA1 and ABCG1 begin to predominate. The
most important of these pathways involves the efflux of phos-
pholipids and free cholesterol on to lipid-free or lipid-poor
apolipoproteins via ABCA1, as demonstrated by the inability
of ABCA1-knockout mice [20] or patients with Tangier’s dis-
ease (who lack ABCA1) to generate HDL [22]. Although all
Table 1 Structural components contributing to heterogeneity of HDL molecule
Shape Subclasses (size/density) Apolipoproteins Lipids Enzymes Acute phase proteins miRNAs
Discoidal (Nascent) HDL2b (Largest / Least Dense) ApoA (I, II, IV, V) Cholesterol LCAT SAA miR-92a
Spherical (Mature) HDL2a ApoC (I, II, III, IV) Cholesterol esters PLTP LBP miR-126
HDL3a ApoD Triglycerides CETP Fibrinogen miR-150
HDL3b ApoE Glycerophosphlipids Lp-PLA2 C3 miR-223
HDL3b (Smallest / Most Dense) ApoF Sphingolipids MPO A1AT
ApoH PON-1
ApoJ
ApoM
HDL, high-density lipoprotein; Apo, apolipoprotein; LCAT, lecithin cholesterol acyl-transferase; PLTP, phospholipid transfer protein; CETP, cholesterol
ester transfer protein; Lp-PLA2, lipoprotein-associated phospholipid A2; MPO, myeloperoxidase; PON, paraoxonase; SAA, serum amyloid A; LBP,
lipopolysaccharide binding protein; C3, complement C3; A1AT, alpha-1-anti-trypsin
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HDL-associated apolipoproteins are capable of accepting cho-
lesterol from ABCA1, interactions with ApoA-I account for
the majority of the response [23]. As is the case for passive
diffusion, LCAT-mediated esterification of cholesterol on
these newly formed nascent HDL particles reduces free extra-
cellular free cholesterol levels by trapping them as esters with-
in the HDL core; with this process both maintaining the con-
centration gradient and resulting in the development of mature
spherical HDL particles capable of mediating further efflux
through ABCG1 receptors [24]. Once transferred to HDL,
cholesterol esters are then returned to the liver for biliary ex-
cretion in one of two ways—they may be exchanged for tri-
glycerides in VLDLs and other remnant lipoproteins by
CETP, thereby enabling their uptake and excretion via hepatic
LDL receptors, or theymay be selectively removed fromHDL
directly via its binding to hepatic SR-BI [25].
Endothelial Nitric Oxide Bioavailability
Diminished nitric oxide (NO) bioavailability is a hallmark of
the vascular disease process, and is thought to underpin every
stage of atherosclerosis [26]. The first evidence of HDL’s abil-
ity to directly promote endothelial NO production came in the
early 2000s, where the addition of HDL to cultured
endothelial cells was shown to directly stimulate endothelial
NO synthase (eNOS) activation in vitro [27]. In this ground-
breaking study, the authors demonstrated an essential role for
both ApoA-I and SR-BI in NO generation, as removal of the
former using antibodies, or the latter using SR-BI knockout
mice, resulted in a loss of effect. However, the use of purified
ApoA-I in place of HDL also failed to elicit a response, sug-
gesting a necessary involvement of other components within
the HDL particle for eNOS phosphorylation. Later research
identified a number of HDL-bound bioactive phospholipids—
namely sphingosylphosphorylcholine (SPC), sphingosine-1-
phosphate (S1P), and lysosulfatide (LSF)—as at least partially
responsible [28], with the binding of these to sphingosine-1-
phosphate receptor 3 (S1P3) demonstrated to stimulate vaso-
relaxation via the activation of phosphatidylinositol 3-
kinase(PI3K)/Akt and mitogen-activated protein kinase
(MAPK) pathways [29]. In addition to ApoA-I and SR-BI,
additional ABCG1 pathways are also likely contribute to this
response. HDL-mediated efflux of 7-ketosterol via ABCG1
has also been shown to improve NO release by preventing
the generation of NO-scavenging reactive oxygen species
within the endothelium, while cholesterol efflux via the same
receptor has been shown to elicit similar responses via a re-
duction in eNOS/caveolin interactions [30, 31].
Fig. 2 Mechanistic pathways underlying reverse cholesterol transport
from macrophages to liver. HDL-mediated RCT involves the removal
of cholesterol from lipid-laden macrophages, where it may then be
transported back to the liver for biliary excretion. In healthy individuals,
nascent and mature HDL particles accept cholesterol from lipid-laden
macrophages within the vascular wall via an interaction of ApoA-I with
ABCA1 and ABCG1 receptors. Following their esterification by the en-
zyme LCAT, these cholesterol particles may undergo selective uptake to
the liver via the interaction of HDL and hepatic SR-BI, or may be trans-
ferred by CETP to VLDL/LDL for hepatic uptake via LDL-R. In condi-
tions of chronic disease or inflammation, numerous changes in this path-
way have been observed that may render it dysfunctional and potentially
increase atherosclerotic risk. These changes include the oxidation or dis-
placement of ApoA-I, alterations in the activity of enzymes such as LCAT
or CETP, and reduced binding of HDL to receptors such as ABCG1 or
SR-BI
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Anti-oxidant and Anti-inflammatory Capacity
An accumulation of foam cells within the vascular wall is
another key process of atherosclerotic disease, initiated via
the uptake of circulating LDL-c and its subsequent oxidation
by reactive oxygen species (ROS) and pro-inflammatory en-
zymes such as MPO within the sub-endothelial space. This
oxLDL is subsequently taken up by scavenger receptors on
macrophages, triggering a cascade of further oxidative and
inflammatory responses which encourage the promotion of
endothelial adhesion molecule expression and increased
monocyte infiltration within the vessel wall. HDL has been
shown to exert multiple antioxidant and anti-inflammatory
effects that may reduce this vicious circle of oxidation/
monocyte infiltration, such as an ability to protect endothelial
and smooth muscle cells from the cytotoxic effects of oxLDL
[32–34] in vitro. This effect is likely to be attributed to a
variety of mechanisms. For example, increases in NO bio-
availability (as described in the previous section) likely con-
tribute at least in part to this response, as do the presence of
multiple antioxidant enzymes carried within HDL’s protein
cargo. The most studied of these enzymes is the antioxidant
enzyme paraoxonase-1 (PON-1), although roles for other en-
zymes such as lipoprotein-associated phospholipid A2 (Lp-
PLA2) [35] and LCAT [36] have also been demonstrated.
The presence of PON-1 has been shown to protect both
HDL and LDL from oxidation in vitro [33, 37], while its
absence (using PON-1 knockout mice) has been demonstrated
to have the opposite effect [38]. Interactions with ApoA-I
appear to be crucial for its activity, as demonstrated by the
significantly increased capacity for PON-1 to prevent LDL
oxidation and promote RCT in HDL particles containing
ApoA-I as opposed to those containing ApoA-II or IV [39].
Additional antioxidant effects of ApoA-I also likely contribute
to HDL’s antioxidant properties via its ability to directly bind
and remove oxidised lipids from LDL particles within the
vascular wall, as treatment of arterial cell walls with ApoA-I
or an Apo-AI mimetic peptide in vitro prevents the oxidation
of LDL, as does injection of ApoA-I into both mice and
humans [40, 41]. HDL has also been shown in a number of
studies to reduce superoxide production in endothelial cells
treated with tumour necrosis factor alpha (TNF-α) [42–44],
possibly through inhibitory effects on nicotinamide adenine
dinucleotide phosphate (NADPH)-oxidases mediated through
HDL-associated lysosphingolipids and their interaction with
S1P3 and SR-BI receptors [45]. Both this pathway and others
have also been shown to have downstream effects on the pro-
duction of numerous inflammatory-mediated adhesion mole-
cules such as vascular and intercellular adhesion molecules
(VCAM-1 and ICAM-1) [46], E-selectin [28], and monocyte
chemoattractant protein-1 (MCP-1) [45, 47], reducing their
expression and limiting monocyte transmigration across the
vascular wall. Furthermore, ABCA1-mediated cholesterol
efflux to ApoA-I may also provide additional suppression
through the activation of anti-inflammatory signalling mole-
cules during reverse cholesterol transport [48].
HDL Structure and Dysfunction in Chronic
Inflammation: When “Good Cholesterol”
Turns Bad
Inflammation Alters HDL Structure
The concept that individuals with chronic disease may have
structurally modified and potentially dysfunctional HDL was
initially suggested in the mid-1990s, where evidence was pro-
duced for the first time showing the replacement of ApoA-I
and paraoxonase-1 (PON-1) during an acute inflammatory re-
sponse with acute phase proteins such as ceruloplasmin and
serum-amyloid A (SAA) [47]. In this seminal study, the au-
thors further noted that the antioxidant and anti-inflammatory
vasoprotective properties of these modified HDL particles
were also lost—or in certain cases—even completely reversed,
suggesting that conformational changes in the HDL particle
may have negatively affected its function. Since then, wide-
ranging structural changes have been reported in a variety of
inflammatory disease states, many of which have been impli-
cated in the generation of a dysfunctional phenotype which
may act to increase atherosclerotic risk. The most well-
studied of these is the incorporation of acute phase proteins
such as SAA, symmetric dimethylarginine (SDMA), lipopoly-
saccharide binding protein (LBP), alpha-1-antitrypsin (A1AT),
or fibrinogen into HDL’s protein cargo [49]. These changes in
turn result in reciprocal and detrimental reductions in ApoA-I,
a decrease in the activity of HDL-associated antioxidant en-
zymes such as PON-1 and Lp-PLA2, and an increased pres-
ence of inflammatory enzymes and lipid peroxidation products
such as myeloperoxidase (MPO) and malondialdehyde
(MDA) [49]. Furthermore, compositional changes in HDL’s
lipid cargo—such as the enrichment with triglycerides com-
monly observed in hypertriglyceridaemic states—may further
affect particle size and density, and therefore functional ability.
Inflammation Reduces Reverse Cholesterol Transport
(RCT)
While a reduction in cholesterol efflux is a well-established
aspect of the innate immune system during acute infec-
tions, it may have long-term negative implications under
conditions of chronic inflammatory stress [15]. Numerous
studies have shown that this vital homeostatic process may
become impaired by a number of structural and conforma-
tional changes within HDL particles exposed to acute or
chronic inflammatory conditions. The incorporation of
SAA has been shown to impair cholesterol efflux in some
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[50–53], but not all [42, 54], studies. These changes may
arise through the displacement of atheroprotective compo-
nents such as ApoA-I or PON-1 within the HDL particle
itself [50], or by interactions with cell membrane-bound
receptors responsible for binding HDL during the RCT
process. In mice overexpressing SAA, reduced binding of
HDL to SR-BI and a reduction in selective hepatic choles-
terol ester uptake from HDL has been observed in conjunc-
tion with elevated levels of lipid-free SAA, suggesting a
reduced capacity for the liver to remove cholesterol esters
for excretion [53]. Further upstream in the RCT pathway,
genetic ablation of SAA has been observed to preserve
cholesterol efflux in mice following an endotoxin chal-
lenge, whereas the same challenge in humans resulted in
progressive decreases in efflux capacity in line with eleva-
tions in the content of HDL-incorporated SAA [51].
Furthermore, an increased affinity for HDL to bind to pro-
teoglycans at peripheral sites has also been demonstrated
following SAA elevation in endotoxin-injected mice [55].
This effect is again virtually abolished following SAA
knockout, suggesting that the incorporation of SAA into
HDL may further impair RCT through the entrapment of
HDL within vascular lesions, where its contents may sub-
sequently be liable to oxidation or enzymatic modification
that render it more atherogenic [55]. In support of this, a
number of studies have demonstrated extensive structural
and functional changes within HDL particles located with-
in the vessel wall in comparison to those circulating in the
bloodstream [56–58], resulting in a substantially dysfunc-
tional HDL phenotype which is unable to promote choles-
terol efflux. For example, ApoA-I isolated from human
atherosclerotic plaques has been shown to be lipid-poor,
heav i ly ox id i sed by the in f l ammato ry enzyme
myeloperoxidase (MPO), and virtually devoid of any cho-
lesterol acceptor activity [59]. This dysfunctional form of
ApoA-I—which may also be caused by chlorination, nitra-
tion, or sulfoxidation of other amino acid residues—
appears to exert its detrimental effects via multiple sites
of action, including impairment of ABCA1 cholesterol ef-
flux [58, 60, 61] and decreased ApoA-I-induced activation
of LCAT [62]. Further inhibition of ABCA1 via an accu-
mulation of the lipid peroxidation product MDA (a reactive
carbonyl that has been shown to increase in HDL in chron-
ic disease states) has also been demonstrated [63], while
HDL-enrichment with triglycerides has been shown to im-
pact RCT in some, but not all, studies. These latter findings
may perhaps seem counter-intuitive given the finding that
triglyceride-enriched HDL may in fact increase macro-
phage cholesterol efflux [64–66]. However, they are likely
explained by further downstream effects that may affect
overall RCT, including a reduced ability for LCAT to con-
vert free cholesterol to cholesterol esters [64], and a dimin-
ished capacity to deliver these cholesterol esters to hepatic
cells via SR-BI [64, 67]. HDL remodelling due to elevated
PLTP activity may also adversely affect cholesterol accep-
tor ability, and has been shown to result in increased ath-
erosclerotic plaque formation in mice [68].
Inflammation Reduces Endothelial Nitric Oxide
Bioavailability
The ability of HDL to promote endothelial nitric oxide
bioavailability has repeatedly been shown to be impaired
in multiple chronic inflammatory and chronic disease
states [42–44, 69–71]. HDL isolated from patients with
either established coronary heart disease or acute coronary
syndrome has a reduced capacity for NO generation that
appears mediated, at least in part, by activation of endo-
thelial lectin-like oxidised LDL receptor 1 (LOX-1). This
upregulation of LOX-1 has been hypothesised to occur in
response to an excess accumulation of the highly reactive
lipid peroxidation compound MDA, possibly due to the
displacement of antioxidant enzyme PON-1 from within
the HDL particle. These changes in turn result in an in-
creased activation of the eNOS-inhibitor endothelial
PKCβII, ultimately leading to a reduced capacity for en-
dothelial NO generation [71]. Inactivation of PON-1 in
healthy subjects in vitro has been shown to result in de-
creased eNOS phosphorylation at serine residue 1177 (an
eNOS activating site), increased phosphorylation at threo-
nine residue 495 (a deactivating site), and a subsequent
decrease in NO bioavailability. This relationship may be
mediated at least in part by the oxidative transformation of
PON-1 by increased levels of pro-inflammatory enzymes
such as MPO [72], as they have been shown to display
reciprocal relationships. Furthermore, MPO and other oxi-
dative products within HDL may directly bind to and
activate endothelial cells, thereby further reducing NO pro-
duction via eNOS coupling [73, 74].
Inflammation Impairs HDL’s Antioxidant
and Anti-inflammatory Capacity
The first evidence underpinning the concept of HDL ‘dys-
function’ came from the finding that HDL isolated from
rabbits undergoing an acute phase response was unable to
prevent lipid peroxidation or MCP-1 expression [47].
Since then, multiple other pro-inflammatory and pro-
oxidant properties have been attributed to dysfunctional
HDL particles; including an increased capacity to stimulate
NADPH oxidase activity [44], an increased capacity for
endothelial superoxide production [42, 69], an increased
expression of cell adhesion markers such as VCAM-1
[43], and increased eNOS uncoupling [73]. Much of these
functional changes are likely closely linked to those previ-
ously described when addressing reductions in NO
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bioavailability, with the replacement of protective proteins
such as ApoA-I and PON-1 with atypical components such
as MDA and MPO of particular importance. For example,
while in vitro work has highlighted the ability of ApoA-I to
remove seeding molecules responsible for LDL oxidation
[40], this ability is lost in HDL isolated from patients with
established CHD [75]. PON-1 is frequently observed to be
reduced in inflammatory conditions and chronic disease
[42, 47, 69], and genetic-knockout mice lacking PON-1
have been shown to have both impaired antioxidant effects
and increased risk of atherosclerosis [38].
HDL Function in Clinical Populations:
Implications for CVD Risk
Cardiovascular Disease
The cardiovascular disease process has been shown to exert
widespread changes in HDL structure and function which
may accelerate, rather than reduce, future risk of major
adverse events. In a series of studies involving the
LURIC, 4S, and KORA cohorts, the association between
HDL-c and CVD mortality was assessed in almost 9000
patients undergoing coronary angiography who were strati-
fied by median levels of serum SAA and SDMA [76, 77].
Remarkably, while patients with below median levels of
both acute phase proteins showed the traditional inverse
relationship between HDL-c and CVD outcomes, those with
above median levels were observed to have the complete
opposite response—i.e. a significantly increased risk of
CVD mortality as HDL-c levels increased. Similar findings
have also been reported when stratifying risk by levels of
C-reactive protein (CRP) in the PREVEND study [78], and
ApoC-III in two prospective case-control studies analysed
within the Nurses Health and Health Professionals Follow-
Up Studies [79], suggesting that stratification by inflamma-
tory burden in CVD may help to identify the independent
effects of ‘biologically effective’ and ‘biologically ineffec-
tive’ HDL particles. When assessing HDL function directly,
cholesterol efflux capacity has been shown to be decreased
in patients with CHD [80], while numerous endothelial pro-
tective functions appear to be impaired. Reduced NO bio-
availability is evident in HDL isolated from patients with
both established coronary heart disease and acute coronary
syndrome [71]. Furthermore, and in contrast to its usual
antioxidant and anti-inflammatory functions, HDL isolated
from patients with CHD has also been shown to promote
rather than protect against LDL oxidation [47, 75], as well
as increasing the expression of adhesion markers such as
MCP-1 [47], and promoting endothelial superoxide produc-
tion in the presence of TNF-α [71].
Type 2 Diabetes
HDL isolated from patients with type 2 diabetes demonstrates
many of the structural and functional alterations previously
described for CVD. Structural changes include increased
SAA levels due to underlying low-levels of chronic inflam-
mation [81], increased triglyceride content due to insulin re-
sistance and elevated CETP activity [82], decreased ApoA-I
and S1P due to displacement by other proteins [83], and in-
creased oxidised lipids and advanced glycation end products
(AGE) due to increased levels of systemic oxidative and
glycaemic stress [84]. Cholesterol efflux is reduced [85]—
possibly due to an impairment of both ABCA1 and SR-BI
mediated pathways through oxidation and AGE—and LCAT
activity is impaired [86]. Widespread impairments in the en-
dothelial protective effects of HDL are also evident, as dem-
onstrated by a recent study in which HDL isolated from pa-
tient with type 2 diabetes demonstrated impaired NO
bioavailabilty, increased MPO and NADPH oxidase activity,
increased superoxide production, and increased lipid peroxi-
dation [44].
Chronic Kidney Disease
The presence of reduced renal function in chronic kidney dis-
ease (CKD) leads to an accumulation of acute phase proteins
within a circulating uremic milieu, many of which are capable
of negatively altering HDL structure and function. HDL iso-
lated from patients on haemodialysis is enriched with numer-
ous components detrimental to HDL function (e.g. SAA,
ApoC-III, A1AT, and triglycerides), and has been observed
to have a reduced capacity to initiate RCT from macrophages
[87]. Of particular importance in CKD is a significant increase
in the acute phase protein symmetric dimethylarginine
(SDMA), whose incorporation into the HDL particle is asso-
ciated with impairments in HDL-mediated RCT and endothe-
lial NO production in a dose-dependent manner [43, 70, 77].
This effect becomes progressively pronounced as kidney
function declines, as demonstrated by a 40–60% decline in
HDL-mediated endothelial NO bioavailability in patients with
stage 5 CKD as opposed to a 20% increase in healthy controls
[43]. Interestingly, these changes are largely reversed follow-
ing kidney transplantation in children, but not adults—
suggesting that HDL’s vascular protective functions may be
at least partially restored in the young [43]. Using genetic
knockout mice models to investigate the pathways underlying
this relationship, Speer and colleagues identified toll-like re-
ceptor 2 (TLR2) as the likely signalling receptor responsible,
suggesting that structural modifications to HDL caused by
CKD may result in damage-associated molecular patterns
within the HDL particle that trigger a chronic innate immune
response [74]. Further post-translational modifications to oth-
er circulating proteins may also affect function. Albumin
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isolated from haemodialysis patients is heavily oxidised and
markedly impairs cholesterol efflux in vitro; likely due to its
high-affinity for SR-BI reducing binding sites for HDL-
mediated RCT [88].
Autoimmune Diseases
HDL dysfunction has recently been demonstrated in a range
of autoimmune diseases, including type 1 diabetes [89], rheu-
matoid arthritis [90, 91], systemic lupus erythematosus [92],
and primary antiphospholipid syndrome [69]. Despite being at
increased risk of dyslipidaemia, patients with type 1 diabetes
commonly demonstrate elevated—rather than reduced—
levels of HDL-c. Multiple studies have reported the presence
of multiple dysfunctional properties to these particles, howev-
er, including reduced cholesterol efflux capacity [93, 94], re-
duced PON-1 activity [95], increased MPO activity [96], and
decreased levels of S1P [97]. These modifications appear to
be independent of HbA1c [93], and may at least partially
explain the increased risk of CVD in patients with the highest
HDL-c levels [98]. HDL isolated from patients with rheuma-
toid arthrit is, systemic lupus erythematosus, and
antiphospholipid syndrome also display widespread structural
changes, resulting in a pro-inflammatory phenotype that
worsens as systemic inflammatory burden increases [69, 91].
Treatment with anti-inflammatory medications in these pa-
tients may partially reverse these structural and functional
modifications, as evidenced by decreases in SAA and LBP
content, increased NO bioavailability and PON-1 activity,
and decreased SO production in individuals with rheumatoid
arthritis treated with the monoclonal antibodies infliximab and
adalimumab [99, 100].
Periodontitis
Periodontal disease represents one of the most prevalent
chronic inflammatory conditions in the world today, affecting
approximately 20–50% of the global population [101].
Numerous vasoprotective functions of HDL have been shown
to be impaired in periodontal patients compared to age-
matched controls, including impaired endothelial NO bio-
availability, increased superoxide production, and reduced
PON-1 activity [42]. When using an intensive periodontal
treatment intervention as an experimental model of acute in-
flammation, further transient decreases in both endothelial NO
availability and PON-1 activity—but not RCT—are apparent
in the following 24 h, highlighting the vulnerability of HDL to
rapidly remodel when exposed to an inflammatory response.
These changes were accompanied by substantial increases in
acute phase reactants such as SAA, C3, and prothrombin, and
returned to baseline levels following resolution of the inflam-
matory response.
Where Next for HDL as a Therapeutic Target?
Given recent advances in our understanding of HDL’s myriad
functions, a limited number of population studies in recent
years have attempted to link individual markers of HDL func-
tion, rather than HDL-c levels, to future risk of CVD. The
largest and most rigorous of these have used cholesterol efflux
capacity as the functional measure of interest, and have found
increased efflux to be associated with a reduced risk for CVD
in some [102–104], but not all [23], of these studies. In the
largest of these to date, cholesterol efflux capacity was found
to be inversely related to incidence of major CV events in
nearly 3000 adults free from CVD at baseline and followed-
up for over 9 years as part of the Dallas Heart Study (hazard
ratio 0.33 [0.19–0.55] for top quartile of efflux compared to
bottom) [102]. Interestingly, while HDL-c levels were found
to be inversely associated with well-established CV risk fac-
tors such as obesity or insulin resistance, cholesterol efflux
capacity was not, suggesting that changes in RCT may occur
through distinct mechanisms to those affecting overall HDL-c
levels. These findings were supported in a more recent nested
case-control analysis in 3500 middle-aged to elderly individ-
uals participating in the EPIC-Norfolk study, where increased
cholesterol efflux was once again associated with a substan-
tially reduced risk of incident CV events (fully adjusted odds
ratio per SD increase in efflux capacity = 0.80 [0.70–0.90] for
those in the top tertile of cholesterol efflux capacity compared
to those in the bottom) [103].
Alongside hard clinical endpoints, further encouraging
findings relating changes in function to surrogate measures
of CVD risk have also been reported in a number of other
studies. Using carotid intima-media thickness (cIMT) and an-
giographically confirmed presence of CHD as surrogate
markers of atherosclerotic disease progression, Khera and col-
leagues showed a substantially decreased presence of coro-
nary disease in individuals within the top quartile for choles-
terol efflux (OR=0.74 [0.61–0.89]) [105]. In children with
CKD, Shroff et al. reported an inverse relationship between
HDL-mediated NO bioavailability and multiple surrogate
markers of arterial health, including cIMT and pulse-wave
velocity (a measure of arterial stiffness) [43]. Likewise, in a
case-control study of women with and without the autoim-
mune condition primary antiphospholipid syndrome, these
same surrogate measures were found to be inversely related
to PON-1 activity, and were accompanied by additional detri-
mental changes in HDL functionality such as decreased NO
bioavailability and increased SO production [69]. These re-
sults suggest that interventions to modify HDL function, rath-
er than simply increasing HDL-c levels—may still hold ther-
apeutic potential for reducing atherosclerotic risk.
Efforts to translate these into clinical benefits in randomised
trials, however, have once again proven to be challenging. For
example, although 3 months of niacin therapy in patients with
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T2D was shown to significantly improve both HDL-c levels
and numerous measures of HDL function [44], the use of this
same drug in individuals at high risk for CVD displayed no
clinical benefit in either the AIM-HIGH and HPS2-THRIVE
trials [6, 7]. Similar issues were encountered in studies
assessing the efficacy of recombinant ApoA-I infusions as a
therapeutic target, which have been proposed to reduce athero-
sclerotic risk via their promotion of ABCA1-mediated reverse
cholesterol transport. While findings from both animal studies
[106] and a small-scale clinical trial in humans [107] suggested
evidence of atherosclerotic plaque regression, the recent pub-
lication of two large-scale randomised controlled trials utilising
both the wild-type and mutated versions of ApoA-I (the latter
termed ApoA-I Milano and considered to be particularly ben-
eficial) have once again found no clinical benefit, despite in-
creases in cholesterol efflux capacity of up to 90% [108, 109].
It is clear that if modification of HDL function is to be
pursued as a therapeutic target, further experimental studies
are required to identify the most relevant pathways for inter-
vention, and genetic studies are required to provide a causal
link between these pathways and CVD. Once appropriate
pathways are identified, standardisation of high-throughput
functional assays for use in routine clinical practice will also
be essential, as this will permit relationships between HDL
function and CVD risk to be tested in large-scale cohorts and
trials, and will allow comparisons of results between studies.
Of note, all major studies investigating cholesterol efflux to-
date have used different techniques to quantify efflux capac-
ity, an observation which may potentially explain discrepan-
cies in findings reported so far. Most importantly though,
lessons must be learned from previous failings involving
HDL-c, where the presence of observational correlations
were long-considered to represent a causal relationship be-
tween HDL levels and CVD risk. Despite some promising
results relating a number of markers of HDL function to
future risk of disease, successful completion of large-scale
randomised clinical trials altering specific functional proper-
ties of HDL are needed to support the use of HDL function as
a therapeutic target.
Conclusions
Despite HDL-c’s well-established inverse relationship with
CVD risk, it does not play a causal role in CVD risk reduction,
and is therefore an unsuitable target for therapeutic interven-
tion. While our understanding of the mechanisms underlying
HDL function and dysfunction have been significantly en-
hanced in recent years, the wide range of different functions
elicited by HDL, their vulnerability to modification by exter-
nal inflammatory responses, and a lack of standardised assays
for the measurement in routine clinical practice makes the
translation of these findings challenging. While research is
continuing to tease out the complexities of this highly heter-
ogenous particle, potential diagnostic and therapeutic strate-
gies involving the modification of HDL remain elusive.
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